We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co
News

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co
News

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated a new discovery collaboration.

Under the contract extension Evotec will provide integrated drug discovery activities, including high throughput screening, medicinal chemistry and in vitro pharmacology to discover novel, small molecular weight compounds active against an ion channel target selected by Ono. Ono will access Evotec’s ion channel drug discovery platform and expertise and Evotec will receive research funding and milestone payments.

Evotec and Ono have collaborated since March 2008 identifying novel inhibitors for a protease target. Within this collaboration Evotec provides protein crystallography, medicinal chemistry, biology and ADMET services to Ono with the aim of progressing a compound towards clinical development.

“Since we have a high regard for Evotec's wide range of drug discovery technologies, and the existing collaboration with Evotec targeting a protease has progressed as planned, we are now pleased to enter into a new drug discovery agreement on an ion channel with Evotec utilizing their proprietary drug discovery platform. We anticipate the collaboration will result in identifying a novel drug candidate with a high potential” said Kazuhito Kawabata, Ph.D., Managing Director, Research Headquarters at Ono.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to be expanding our collaboration and initiating a new discovery collaboration with Ono, a partner with whom we enjoy a close relationship. This expansion clearly demonstrates the value we bring to our alliance partners in the area of drug discovery. We look forward to continuing working closely with our colleagues at Ono.”
Advertisement